Male Hypogonadism – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Male Hypogonadism – Pipeline Review, H1 2017’, provides an overview of the Male Hypogonadism pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Male Hypogonadism, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Male Hypogonadism and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Male Hypogonadism

The report reviews pipeline therapeutics for Male Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Male Hypogonadism therapeutics and enlists all their major and minor projects

The report assesses Male Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Male Hypogonadism

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Male Hypogonadism

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Male Hypogonadism pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Antares Pharma Inc

Clarus Therapeutics Inc

EndoCeutics Inc

Ferring International Center SA

IASO BioMed Inc

Lipocine Inc

M et P Pharma AG

Medlab Clinical Ltd

Merck & Co Inc

Mereo Biopharma Group Plc

Pantarhei Bioscience BV

Repros Therapeutics Inc

Takeda Pharmaceutical Company Ltd

TesoRx Pharma LLC

Viramal Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Male Hypogonadism - Overview

Male Hypogonadism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Male Hypogonadism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Male Hypogonadism - Companies Involved in Therapeutics Development

Antares Pharma Inc

Clarus Therapeutics Inc

EndoCeutics Inc

Ferring International Center SA

IASO BioMed Inc

Lipocine Inc

M et P Pharma AG

Medlab Clinical Ltd

Merck & Co Inc

Mereo Biopharma Group Plc

Pantarhei Bioscience BV

Repros Therapeutics Inc

Takeda Pharmaceutical Company Ltd

TesoRx Pharma LLC

Viramal Ltd

Male Hypogonadism - Drug Profiles

BGS-649 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corifollitropin alfa - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

enclomiphene citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IAS-167A - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kisspeptin-10 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

leuprolide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Libidua - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LPCN-1111 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSS-722 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

T-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TAK-448 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone enanthate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone propionate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

testosterone undecanoate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Male Hypogonadism - Dormant Projects

Male Hypogonadism - Discontinued Products

Male Hypogonadism - Product Development Milestones

Featured News & Press Releases

Feb 08, 2017: Acerus Announces NATESTO Posters to Be Presented at the Endocrine Society 2017 Annual Meeting

Feb 01, 2017: Aytu BioScience Announces Two Presentations at Endocrine Society 2017 Annual Meeting Highlighting Benefits of Natesto (Testosterone) Nasal Gel in Men

Jan 24, 2017: Acerus Announces Natesto Abstracts To Be Presented At The American Urological Associations Annual Meeting

Jan 18, 2017: Aytu BioScience Announces Two Presentations Highlighting Benefits of Natesto (Testosterone) Nasal Gel in Men at American Urological Association Annual Meeting

Dec 21, 2016: Antares Pharma Announces Submission of New Drug Application for Quickshot Testosterone

Dec 06, 2016: FDA Advisory Committee Discusses Clinical Trial Designs for Obesity-Related Hypogonadism

Nov 30, 2016: Aytu BioScience Announces Study Findings Demonstrating Clinical Improvements in Erectile Function and Mood in Hypogonadal Men Treated with Natesto Nasal Testosterone Gel

Nov 21, 2016: Diurnal Group: First patient dosed in testosterone replacement therapy for hypogonadism

Nov 02, 2016: Antares Pharma Announces Presentations at the Sexual Medicine Society Scientific Annual Meeting

Oct 28, 2016: Antares Pharma Announces Multiple Presentations at the Sexual Medicine Society Scientific Annual Meeting

Oct 05, 2016: Repros Announces Acceptance of Dossier for Enclomiphene for Secondary Hypogonadism by European Authorities

Oct 05, 2016: Acerus Announces Canadian Commercial Launch of NATESTO

Sep 26, 2016: Lipocine Announces Positive Top-Line Phase 2b Study Results for LPCN 1111, a Next Generation Oral Testosterone Replacement Therapy

Sep 22, 2016: Antares Pharma Announces Completion of the QuickShot Testosterone Clinical Program

Sep 12, 2016: Repros Announces Submission of MAA to the European Medicines Agency for Enclomiphene in the Treatment of Secondary Hypogonadism

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Male Hypogonadism, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Male Hypogonadism – Pipeline by Antares Pharma Inc, H1 2017

Male Hypogonadism – Pipeline by Clarus Therapeutics Inc, H1 2017

Male Hypogonadism – Pipeline by EndoCeutics Inc, H1 2017

Male Hypogonadism – Pipeline by Ferring International Center SA, H1 2017

Male Hypogonadism – Pipeline by IASO BioMed Inc, H1 2017

Male Hypogonadism – Pipeline by Lipocine Inc, H1 2017

Male Hypogonadism – Pipeline by M et P Pharma AG, H1 2017

Male Hypogonadism – Pipeline by Medlab Clinical Ltd, H1 2017

Male Hypogonadism – Pipeline by Merck & Co Inc, H1 2017

Male Hypogonadism – Pipeline by Mereo Biopharma Group Plc, H1 2017

Male Hypogonadism – Pipeline by Pantarhei Bioscience BV, H1 2017

Male Hypogonadism – Pipeline by Repros Therapeutics Inc, H1 2017

Male Hypogonadism – Pipeline by Takeda Pharmaceutical Company Ltd, H1 2017

Male Hypogonadism – Pipeline by TesoRx Pharma LLC, H1 2017

Male Hypogonadism – Pipeline by Viramal Ltd, H1 2017

Male Hypogonadism – Dormant Projects, H1 2017

Male Hypogonadism – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Male Hypogonadism, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports